secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001157523-23-000777
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock Q1 net loss $39.4M; Phase 3 SMA trial enrollment on track for 2023
-------------------------------------------------------------------------------

- Net loss of $39.4M ($0.49 per share) vs $8.0M loss in prior year; revenue $0 vs $33.2M.
- Cash, equivalents & marketable securities $275M as of March 31, 2023, funding into 2025.
- Phase 3 SAPPHIRE trial for apitegromab in SMA enrollment completion expected in 2023, top-line data in 2024.
- Phase 1 DRAGON trial for SRK-181 biomarker and clinical update planned for H2 2023.
- Richard Brudnick appointed to Board of Directors in April 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000115752323000777/0001157523-23-000777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000115752323000777/a53395784.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-000777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer